GGrantIndex
← Leaderboards

Iowa City Va Medical Center

Iowa City, IA

Compare ↔
$0
Total funding
148
Grants

Funding over time

peak $0 · FY200925
$1$1$1$0$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

VA$0 · 148

By mechanism

I01$0 · 113
I21$0 · 11
I50$0 · 4
IK1$0 · 1
IK2$0 · 12
IK6$0 · 2

Investigators at Iowa City Va Medical Center

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Largest grants

Control of Human Cytomegalovirus$0
I01 · FY2012 · VA
HPV Persistence and Head and Neck Cancer$0
I01 · FY2012 · VA
Macrophage-Activating MicroRNAs In the Pathogenesis of Leishmaniasis$0
I01 · FY2012 · VA
STEM CELL-DERIVED INSUIN PRODUCING CELLS CORRECT HYPERGLYCEMIA IN DIABETIC MICE$0
I01 · FY2012 · VA
Coronary Dysregulation Associated with Obesity$0
I01 · FY2012 · VA
Mitochondrial-targeted CoQ: Metabolic and Redox Effects and role in Diabetes$0
I01 · FY2012 · VA
Cholinergic Drugs For Reversal Of Visual Deficits In Glaucoma$0
I01 · FY2012 · VA
Prevention of Hemorrhage and Death After Traumatic Blast Injury (TBI)$0
I01 · FY2012 · VA
Heme Oxygenase-1 Inhibition of Hepatitis C Replication$0
I01 · FY2012 · VA
Reducing Stroke Damage in the Brain$0
I01 · FY2012 · VA
Novel Intervention to Influence Muscle Plasticity in Veterans with SCI$0
I01 · FY2012 · VA
Regulation of the Nox1 NADPH Oxidase in Vascular Smooth Muscle Cells$0
I01 · FY2012 · VA
Molecular Mechanisms of Age-related Muscle Loss$0
I01 · FY2012 · VA
Regulation of Leishmania-Associated Macrophage Activities by MicroRNAs$0
IK2 · FY2013 · VA
Suppression of T cell immunity during sepsis$0
I01 · FY2013 · VA
Regulation of the Nox1 NADPH Oxidase in Vascular Smooth Muscle Cells$0
I01 · FY2013 · VA
Contribution of caveolin to diabetic vascular dysfunction$0
I01 · FY2013 · VA
Anti HCV Protease Activities of Metalloporphyrins$0
I01 · FY2013 · VA
Epithelial Sodium Channel Trafficking$0
I01 · FY2013 · VA
Calmodulin kinase II inhibition as novel molecular treatment of hypertension$0
I01 · FY2013 · VA